Abstract
P191 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have